Yayın:
Discovering novel carbonic anhydrase type IX (CA IX) inhibitors from seven million compounds using virtual screening andin vitroanalysis

dc.contributor.authorSalmas, Ramin Ekhteiari
dc.contributor.authorSenturk, Murat
dc.contributor.authorYurtsever, Mine
dc.contributor.authorDurdagi, Serdar
dc.contributor.ituauthorYurtsever, Mine
dc.date.accessioned2026-01-25T11:20:30Z
dc.date.issued2015-05-07
dc.description.abstractCarbonic anhydrase type IX (CA IX) enzyme is mostly over expressed in different cancer cell lines and tumor tissues. Potent CA IX inhibitors can be effective for adjusting the pH imbalance in tumor cells. In the present work, we represented the successful application of high throughput virtual screening (HTVS) of large dataset from ZINC database included of ∼7 million compounds to discover novel inhibitors of CA IX. HTVS and molecular docking were performed using consequence Glide/standard precision (SP), extra precision (XP) and induced fit docking (IFD) molecular docking protocols. For each compound, docking code calculates a set of low-energy poses and then exhaustively scans the binding pocket of the target with small compounds. Novel CA IX inhibitor candidates were suggested based on molecular modeling studies and a few of them were tested using <i>in vitro</i> analysis. These compounds were determined as good inhibitors against human CA IX target with K<sub>i</sub> in the range of 0.85–1.58 μM. In order to predict the pharmaceutical properties of the selected compounds, ADME (absorption, distribution, metabolism and excretion) analysis was also carried out.
dc.description.urihttps://doi.org/10.3109/14756366.2015.1036049
dc.description.urihttps://dx.doi.org/10.6084/m9.figshare.3100978.v1
dc.description.urihttps://dx.doi.org/10.6084/m9.figshare.3100978
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/25950196
dc.description.urihttps://dx.doi.org/10.3109/14756366.2015.1036049
dc.description.urihttps://hdl.handle.net/20.500.12501/946
dc.description.urihttps://aperta.ulakbim.gov.tr/record/58441
dc.description.urihttps://doi.org/https://doi.org/10.3109/14756366.2015.1036049
dc.description.urihttps://doi.org/https://doi.org/20.500.12501/946
dc.identifier.doi10.3109/14756366.2015.1036049
dc.identifier.eissn1475-6374
dc.identifier.endpage9
dc.identifier.issn1475-6366
dc.identifier.openairedoi_dedup___::88c1d3eab5c34f34981fb70f508d44f7
dc.identifier.orcid0000-0003-3888-5070
dc.identifier.orcid0000-0001-6504-7182
dc.identifier.orcid0000-0002-0426-0905
dc.identifier.startpage1
dc.identifier.urihttps://hdl.handle.net/11527/50557
dc.language.isoeng
dc.publisherInforma UK Limited
dc.relation.ispartofJournal of Enzyme Inhibition and Medicinal Chemistry
dc.rightsOPEN
dc.sdg.typeGoal 3: Good Health and Well-being
dc.subjectDose-Response Relationship, Drug
dc.subjectMolecular Structure
dc.subjectcarbonic anhydrase
dc.subjectDrug Evaluation, Preclinical
dc.subjectmolecular docking
dc.subjectMolecular Dynamics Simulation
dc.subjectvirtual screening
dc.subjectMolecular Docking Simulation
dc.subjectStructure-Activity Relationship
dc.subjectADME
dc.subjectAntigens, Neoplasm
dc.subjectCell Line, Tumor
dc.subjectHumans
dc.subjectCarbonic Anhydrase IX
dc.subjectCarbonic Anhydrase Inhibitors
dc.subjectCA IX inhibitors
dc.subjectCarbonic Anhydrases
dc.titleDiscovering novel carbonic anhydrase type IX (CA IX) inhibitors from seven million compounds using virtual screening andin vitroanalysis
dc.typeArticle
dspace.entity.typePublication
person.identifier.orcid0000-0001-6504-7182

Dosyalar

Koleksiyonlar